GlaxoSmithKline PLC ADR
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $8,012,000 | $8,012,000 | $7,884,000 | $7,363,000 |
Gross Profit | 5,615,000 | 5,615,000 | 5,803,000 | 5,426,000 |
EBITDA | 1,171,000 | 1,171,000 | 2,854,000 | 2,532,000 |
EBIT | 220,000 | 220,000 | 2,215,000 | 1,983,000 |
Net Income | -58,000 | -58,000 | 1,173,000 | 1,046,000 |
Net Change In Cash | 8,012,000 | 8,012,000 | 7,884,000 | 7,363,000 |
Free Cash Flow | 1,312,000 | 1,312,000 | 440,000 | 376,000 |
Cash | 3,192,000 | 3,192,000 | 2,962,000 | 2,790,000 |
Basic Shares | 2,040,000 | 2,040,000 | 2,061,000 | 4,113,000 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $30,328,000 | $29,324,000 | $34,114,000 | $34,099,000 |
Gross Profit | 21,252,000 | 19,770,000 | 22,511,000 | 22,395,000 |
EBITDA | 9,083,000 | 8,601,000 | 7,756,000 | 8,100,000 |
EBIT | 6,789,000 | 6,454,000 | 5,634,000 | 5,749,000 |
Net Income | 4,928,000 | 14,956,000 | 4,385,000 | 5,749,000 |
Net Change In Cash | 30,328,000 | 29,324,000 | 34,114,000 | 34,099,000 |
Free Cash Flow | 4,004,000 | 5,145,000 | 5,021,000 | 6,202,000 |
Cash | 2,936,000 | 3,723,000 | 4,274,000 | 6,292,000 |
Basic Shares | 4,111,000 | 2,042,000 | 1,620,800 | 2,015,200 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $1.29 |
2024-06-30 | $1.10 |
2024-03-31 | $1.09 |
2023-12-31 | $0.72 |
